Merck & Co. reported fourth-quarter revenue that beat Wall Street expectations, fueled by its cancer blockbuster and new launches. However, a full-year sales forecast that fell slightly short of estimates highlights the challenges of generic competition and pricing pressures facing the pharma giant.
Amidst the blockbuster success of its weight-loss drugs, pharmaceutical giant Eli Lilly is making a strategic push into genetic medicine, securing exclusive rights to novel hearing loss treatments through a major partnership with German biotech Seamless Therapeutics.
In a strategic shift, PepsiCo announces price reductions for popular snacks like Doritos and Cheetos in the U.S., responding to consumer backlash over high costs and adapting to market changes driven by weight-loss drugs.
Becton Dickinson (BD) sees its price target raised by Piper Sandler as the medtech giant prepares to overhaul its financial reporting structure and invests heavily in prefillable syringe production to meet booming demand for GLP-1 and biologic drugs.
CNBC's Jim Cramer has placed PepsiCo on his radar, expressing specific concerns that the consumer giant's Frito-Lay snack division faces headwinds from the rising popularity of GLP-1 weight-loss drugs, even as the stock shows recent strength.
Eli Lilly's $3.5 billion investment in a new Pennsylvania facility for injectable weight-loss drugs, including retatrutide, spotlights its aggressive expansion in the obesity market. This strategic move, coupled with strong analyst sentiment and upcoming earnings, intensifies focus on the company's growth trajectory and premium valuation.
The pharmaceutical giant is set to release quarterly results before the bell Wednesday, with Wall Street anticipating another period of blockbuster revenue growth driven by its GLP-1 drugs.
While Wall Street obsesses over GLP-1 weight-loss drugs, Novo Nordisk's foundational diabetes business continues to deliver robust growth and exceptional returns on assets, presenting a durable investment thesis often overshadowed by the obesity narrative.
CNBC's Jim Cramer tempered enthusiasm for Novo Nordisk stock, suggesting investors hold rather than buy after its massive gains driven by blockbuster weight-loss drugs.
The surge in popularity of weight-loss drugs like Ozempic and Wegovy is sending shockwaves far beyond the pharmacy, fundamentally altering consumer spending, challenging major corporations, and forcing a broad economic recalibration.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility dedicated to next-generation weight-loss drugs, signaling a long-term strategic commitment to the obesity market amid intense competition.
Pharmaceutical leader Eli Lilly will build a new manufacturing facility in Lehigh County, marking the largest life sciences investment in Pennsylvania history and bolstering U.S. production of next-generation weight-loss drugs.
Eli Lilly announces a massive new manufacturing facility in Pennsylvania, part of a strategic pivot by major drugmakers to onshore production amid trade tensions and soaring demand for weight-loss drugs.
Amneal Pharmaceuticals' shares have surged over 64% in the past year, prompting investors to question if the rally still has room to run. A closer look at valuation metrics suggests the generic drugmaker may still be trading at a significant discount to its intrinsic value.
In a landmark deal, AstraZeneca has licensed a suite of next-generation weight-loss drugs from China's CSPC, aiming to challenge the dominance of Lilly and Novo Nordisk with longer-acting monthly injectables.
While stocks priced between $10 and $50 can appear to offer an attractive blend of accessibility and maturity, not all are built on solid foundations. We examine three such companies where underlying business risks may outweigh the appeal of a low share price.
Eli Lilly shares surged Wednesday after the pharmaceutical giant projected robust revenue growth through 2026, fueled by its weight-loss drug portfolio. The upbeat outlook contrasted sharply with rival Novo Nordisk, whose stock tumbled following a weaker-than-expected sales forecast.
Eli Lilly & Co. shares surged 10% after the pharmaceutical giant posted Q4 2025 results that smashed analyst forecasts and issued a robust 2026 outlook, powered by unprecedented demand for its GLP-1 drugs Mounjaro and Zepbound.
The Danish pharma giant reported strong 2025 results driven by its blockbuster obesity and diabetes drugs but forecast a challenging 2026 due to pricing pressures and looming patent expiries, even as it rolls out a pivotal new oral weight-loss treatment in the U.S.
The Danish pharmaceutical giant warns of its first sales decline in years for 2026, citing U.S. pricing pressures and patent expirations, sending shockwaves through investor confidence and highlighting intensifying competition in the lucrative obesity drug market.
